Major and Macular Branched Retinal Venous Occlusion

N/ACompletedNCT01219205

Hallym University Medical Center46 enrolled

Overview

Although it is important in the clinical management to classify BRVO into subtypes based on the location of the occlusion (major or macular), few studies have provided such information\[8,9\]. The aim of this study was to evaluate the outcome of patients with macular edema due to Branch retinal vein occlusion who were treated with intravitreal bevacizumab injection and to determine the concentrations of cytokines in the aqueous humor according to the site of the occlusion.

Branch retinal vein occlusion is the second most frequent major retinal vascular disease after diabetic retinopathy. One of the main reasons for visual loss in BRVO is the development of macular edema. Treatment options for BRVO include grid laser treatment, intravitreal injection of steroids, surgical procedures, and off-label treatment with intravitreal anti-vascular endothelial growth factor (VEGF) agents. During recent years, intravitreal anti-VEGF treatment with bevacizumab has been shown to efficiently reduce macular edema and improve visual acuity in numerous case series and prospective or retrospective studies.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Macular Edema

Interventions

intravitreal bevacizumabPROCEDURE

Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * macular edema involving the center of the fovea with a minimum central macular thickness at baseline of ≥250 μm Exclusion Criteria: * previous vitreoretinal surgery, intravitreal injections or laser treatment

Locations (1)

Ji Won Lim

Chuncheon, Gangwon-do, South Korea

Outcomes

Primary Outcomes

efficacy of intravitreal bevacizumab

the number on intravitreal bevacizumab during follow-up

Time frame: baseline and 12 months after initial injection

Secondary Outcomes

cytokine levels in aqueous humor

cytokine levels in aqueous humor before bevacizumab injection

Time frame: before intravitreal injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.